Le Lézard
Classified in: Health
Subject: NPT

NFL And American Cancer Society Expand Crucial Catch Campaign To Support Multiple Cancers



ATLANTA, Oct. 5, 2017 /PRNewswire-USNewswire/ -- This year, the National Football League and the American Cancer Society (ACS) are expanding their efforts to support the fight against cancer through the "Crucial Catch: Intercept Cancer" campaign. After nearly a decade of supporting breast cancer, the NFL and ACS have broadened the campaign to include early detection and risk reduction efforts for other cancers to increase the impact of the campaign.

American Cancer Society Logo (PRNewsfoto/American Cancer Society)

Since 2009, the NFL has raised more than $18 million for ACS through the partnership. Money raised through Crucial Catch this season will be directed toward efforts to encourage people to get screening tests for three cancers: breast, colorectal and cervical. Funding will continue to support the American Cancer Society's Community Health Advocates implementing Nationwide Grants for Empowerment and Equity (CHANGE) program, which provides outreach and cancer screenings to individuals in underserved communities. Since 2012, grant recipients have contributed to nearly 150,000 screenings and 450,000 education and outreach interventions.

"As one our most powerful partners in the fight against cancer over the last decade, the NFL is working together with the American Cancer Society to truly attack cancer from all angles. With the league's expanded focus on multiple cancers, we are poised for even greater relevance, and fans around the country can benefit from our critical work in saving lives from cancer," said Sharon Byers, chief development and marketing officer for the American Cancer Society.

As part of the campaign, the NFL and ACS launched a new, digital tool, The Defender, which provides the public with free personalized tips to reduce their cancer risk. In the spirit of 'The Best Defense is a Good Offense,' people can enter information about their height, weight, exercise regimen and more. The tool will analyze and provides personalized recommendations on what they can do to reduce their risk of getting cancer. The Defender was funded by the NFL and developed by ACS and can be found at TheDefender.cancer.org.

"Many people want to reduce their risk for cancer, but they don't know where to start," said Dr. Richard Wender, chief cancer control officer for the American Cancer Society. "That's where The Defender comes in. Fans can answer a few short questions, and The Defender will create a personalized game plan for improving health and reducing cancer risk."

For most Americans who do not use tobacco, the most important cancer risk factors that can be changed are body weight, diet and physical activity.

Although genetics influence cancer risk, there are things you can do to tip the scales in your favor. Avoiding tobacco products, staying at a healthy weight, exercising regularly, and eating a healthy diet may reduce a person's lifetime risk of developing or dying from cancer.

Although these healthy choices can be made by each of us, they may be helped or slowed by the social, physical, economic, and regulatory environment in which we live. Community efforts are needed to create an environment that makes it easier for us to make healthy choices when it comes to diet and physical activity. To find out more, go to cancer.org.

 

SOURCE American Cancer Society


These press releases may also interest you

at 18:34
Blessed Herbs Cafe and Mount Zion Rastafarian Church founder and practicing Rasta George Metropoulos today announced the launch of the organization's first holiday season food and cash drive. Directly benefiting the neighborhood's less fortunate...

at 11:40
A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescartatm, remain in remission 15...

at 10:47
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriahtm (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r)...

at 10:30
For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight...

at 08:48
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality...

at 08:32
The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical genomics are paving the way to novel approaches for the diagnosis, management, and treatment of patients with...




News published on 5 october 2017 at 13:13 and distributed by: